期刊名称：MOLECULAR PHARMACOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Molecular Pharmacology welcomes manuscripts for consideration that report new information on drug action or selective toxicity at the molecular level. The Editors encourage submissions that shed light upon molecular mechanisms. These may include, for example, studies of receptors, signaling, pathways, enzymes,channels, and transcriptional mechanisms. Studies that report the development of novel reagents or technologies that are of broad applicability or yield new molecular insights are also encouraged. While Molecular Pharmacology attempts to publish studies with a strong component of biological experimentation, the journal also welcomes studies that involve molecular modeling relevant to drug design or drug action.
Instructions to Authors
Scope of Submitted Manuscripts
Molecular Pharmacology welcomes manuscripts for consideration that report new information on drug action or selective toxicity at the molecular level. The Editors encourage submissions that shed light upon molecular mechanisms. These may include, for example, studies of receptors, signaling, pathways, enzymes, channels, and transcriptional mechanisms. Studies that report the development of novel reagents or technologies that are of broad applicability or yield new molecular insights are also encouraged. However, the journal does not typically publish manuscripts in which tool discovery is the sole focus. Instead, we encourage manuscripts in which novel reagents or tools are used to gain fundamental new mechanistic insights that are important for a given area of pharmacology. While Molecular Pharmacology attempts to publish studies with a strong component of biological experimentation, the journal also welcomes studies that involve molecular modeling relevant to drug design or drug action that also include significant experimental data sets.
Submission of Manuscripts
ALL manuscripts submissions must be made through the journal's online manuscript system at http://submit-molpharm.aspetjournals.org. Submissions mailed to the editorial office will not be processed.
If you are using the system for the first time, you must create an account before you can submit a paper. To do so, please click "Create a new account". Complete instructions for using the online manuscript system are provided in the Author Area; click on "Help with Online Submission".
After submitting your manuscript online, please mail or fax (credit cards only) the items detailed below in a) and b) to Molecular Pharmacology, ASPET Journals Department, 9650 Rockville Pike, Bethesda, MD 20814-3995; telephone: 301-634-7063; fax: 301-634-7158.
a) A check or institutional purchase order for $50.00 for the manuscript handling fee (checks must be in U.S. dollars, drawn on a U.S. bank, MICR encoded at the bottom of the check, and payable to ASPET). VISA, MasterCard, and American Express credit cards are also accepted. When paying by credit card, provide the cardholder's name, complete card number, expiration date, and include the three digits located on the back of a Visa or MasterCard in the signature box or the four digits on the front of the American Express card above the raised numbers. Please state whether the card is Visa, MasterCard, or American Express (no other cards are acceptable), and include the cardholder's signature. Wire transfers are not permitted.
b) A completed copy of the Authorship Responsibility, Financial Disclosure and Copyright Transfer form signed by all authors [Fill-In PDF Version of Authorship Responsibility, Financial Disclosure and Copyright Transfer Form]. Submission of a manuscript amounts to assurance that it has received proper clearance from the author's company or institution, that it has not been copyrighted, published, or accepted for publication elsewhere, that it is not currently being considered for publication elsewhere, and that it will not be submitted elsewhere while under consideration by Molecular Pharmacology. Indicate all potential conflicts of interest.
The corresponding author is responsible for obtaining permission from the copyright owner to reproduce or modify figures and tables and to reproduce text (in whole or in part) from previous publications; permissions must allow electronic reproduction as well as print. A permissions request form is available from the online Instructions to Authors. Signed permissions forms must be submitted with the manuscript and be identified as to the relevant item in the manuscript (e.g., "permissions for Fig. 1"). In addition, a statement indicating that the material is being reprinted with permission must be included in the relevant figure legend or table footnote of the manuscript. Reprinted text must be enclosed in quotation marks, and the permission statement must be included as running text or indicated parenthetically.
Manuscripts must be in English, typewritten using Arial or Times New Roman fonts only, and double-spaced throughout, including references, tables, and figure legends, with at least 1 inch (25 mm) margins.
The American Society for Pharmacology and Experimental Therapeutics requires authors to affirm that original studies reported in the journals of the Society have been carried out in accordance with the Declaration of Helsinki and/or with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health.
Organization of the Manuscript
Manuscripts should contain the following sections in the order listed. Each section should be titled and begin on a new page. All pages, excluding figure pages, should be numbered consecutively.
1. Title page. This should contain the complete title of the article, the names of all authors, and the primary laboratory of origin. Affiliation should be indicated by author initials only. Financial support for the research should not be on this page but indicated as an unnumbered footnote to the title and included with other footnotes on a separate page following the References section.
2. Running title page. The running title page should contain the following:
- a) A running title, which conveys the sense of the full title (not to exceed 60 characters, including spaces and punctuation). Commonly used abbreviations (e.g., "ATP", "Ach", etc.) may be used.
- b) The name, address, telephone and fax numbers, and e-mail address of the corresponding author. Only one author may be designated as the corresponding author. The e-mail address will also be used as a hypertext link in the online version of the paper.
- c) The number of text pages, number of tables, figures, and references, and the number of words in the Abstract, Introduction, and Discussion (each item should be placed on a separate line).
- d) A list of nonstandard abbreviations used in the paper. A standard abbreviations list is available from this link. The use of abbreviations should be minimized to enhance readability and comprehension of the text.
3. Abstract. The abstract should concisely present the hypothesis being tested, general methods, results, and conclusions. Abstracts of more than 250 words will not be accepted. A word is one or more characters bounded by white space. The abstract must be a single paragraph. IMPORTANT: If your manuscript is accepted, the abstract entered into the online metadata form will appear online EXACTLY the way you enter it during the submission process. Please make sure to code all special characters, including sub- and superscripts, using the codes available from the online submission system. For revisions, update the abstract, if changed from the original.
4. Introduction. This section must contain a clear statement of the aims of the work or of the hypotheses being tested. A brief account of the relevant background that supports the rationale of the study should also be given. The length of the Introduction should not exceed 750 words.
5. Materials and Methods. This section should contain explicit, concise descriptions of all new methods or procedures employed. Whereas modifications of previously published methods must be described, commonly used procedures require only a citation of the original source. Descriptions of methods must be sufficient to enable the reader to judge the accuracy, reproducibility, and reliability of the experiment(s). The name and location (city and state or country) of commercial suppliers of chemicals, reagents, and equipment must be given. Sources of compounds, reagents, and equipment not available commercially should be identified by name and affiliation here or in the Acknowledgments section.
6. Results. Contained in this section are the experimental data, with no discussion of their significance. Results are typically presented in figures or tables, with no duplication of information in the text. If a table or figure includes less than four values, the data should be presented in the text rather than as a separate table or figure. Magnitudes of variables reported should be expressed in numerals. Generally, units are abbreviated without punctuation and with no distinction between singular and plural forms (e.g., 1 mg, 25 mg). Sufficient data should be presented to allow for judgment of the variability and reliability of the results. Statistical probability (p) in tables, figures, and figure legends should be expressed as *p < 0.05, **p < 0.01, and ***p < 0.001. For second comparisons, one, two, or three daggers may be used. For multiple comparisons within a table, footnotes italicized in lower case, superscript letters are used and defined in the table legend.
7. Discussion. Conclusions drawn from the results presented are included in this section. Whereas speculative discussion is allowed, it must be identified as such and be based on the data presented. The Discussion must be as concise as possible and should not exceed 1,500 words.
8. Acknowledgments. The Acknowledgments section is placed at the end of the text. Personal assistance is noted here. Financial support is acknowledged as an unnumbered footnote to the title.
9. References. References are cited in the text by giving the first author's name (or the first and second if they are the only authors) and the year of publication (e.g., Ruth and Gehrig, 1929; McCarthy, 1952; or Kennedy et al., 1960). In the reference list, the references should be arranged alphabetically by author and not numbered. The names of all authors should be given in the reference list. If reference is made to more than one publication by the same author(s) in the same year, suffixes (a, b, c, etc.) should be added to the year in the text citation and in the references list . Journal titles should be abbreviated as given in the Medline abbreviation list linked to the online Instructions to Authors. The total number of references is limited to 40. References to personal communications, unpublished observations, and papers submitted for publication are given in parentheses at the appropriate location in the text, not in the list of references. Only papers that have been officially accepted for publication may be cited as "in press" in the reference list. The authors are responsible for the accuracy of the references. The format for journal article, chapter, book, and publish-ahead-of-print journal article references is as follows:
- Fricks IP, Maddileti S, Carter SRL, Lazarowski ER, Nicholas RA, Jacobson KA, and Harden TK (2008) UDP is a competitive antagonist at the human P2Y14 receptor. J Pharmacol Exp Ther325: 588-594.
- Kappas A (2002) Development of heme oxygenase inhibitors for the prevention of sever jaundice in infants: studies from laboratory bench to newborn nursery, in Heme Oxygenase in Biology and Medicine (Abraham NG, Alam J, and Nath KA eds) pp 3-17, Kluwer Academic/Plenum Publishers, New York.
- Wilson JH and Hunt T (2008) Molecular Biology of the Cell: A Problems Approach, 5th ed. Garland Science, New York.
- Hanada K, Ikemi Y, Kukita K, Mihara K, and Ogata H (2008) Stereoselective first-pass metabolism of verapamil in the small intestine and liver in rats. Drug Metab Dispos doi: 10.1124/dmd.107.020339.
10. Footnotes. Footnotes should be listed on a separate page and presented in the following order:
- a) Unnumbered footnote providing the source of financial support. This information must be in the form of a sentence with the name of the funding agency written out in full. Research funded by the NIH, the Wellcome Trust, the Howard Hughes Medical Institute, and the Research Councils UK and its agencies MUST include the grant number in square brackets:
- This work was supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant XXXX].
Multiple grant numbers should be separated by a comma and a space. Where the research was supported by more than one agency, the different agencies should be separated by a semi-colon with "and" before the final funder:
- This work was supported by the Wellcome Trust [Grants XXX, YYY]; the National Institutes of Health National Institute of Cancer [Grants ZZZ, AAA]; and the Howard Hughes Medical Institute [Grant BBB].
Funding from these agencies may not be cited without a grant number.
When one or more authors are NIH employees, the following footnote must be included:
- This research was supported [in part] by the Intramural Research Program of the National Institutes of Health [name of institute].
- b) Unnumbered footnote providing thesis information, citation of meeting abstracts where the work was previously presented, etc.
- c) The name and full address (with street address or P.O. box and postal code) and e-mail address of person to receive reprint requests.
- d) Numbered footnotes, using superscript numbers, beginning with those (if any) to authors' names and listed in order of appearance.
11. Legends for figures. Figures are numbered consecutively with Arabic numerals and listed in order rather than one per page. Legends must provide sufficient explanation for the reader to understand the figure independent of the text.
12.Tables. Each table must be double-spaced and begin on a separate page, each page numbered continuous with the rest of the manuscript. Tables are numbered consecutively with Arabic numerals. A brief descriptive title is provided at the top of each table. General statements about the table follow the title in paragraph form. Footnotes to tables are referenced by italicized, lower case, superscript letters and defined beneath the table. Acceptable formats for tables are Word and WordPerfect.
13. Figures. Submit illustrations prepared as specified at http://cjs.cadmus.com/da. Each figure must be uploaded as a separate file in a 600+ dots per inch .tif, .eps, or .jpg format and scaled to fit an 8.5 x 11 inch page. Authors are advised to avoid submitting .ppt files; they do not reproduce as clearly as other formats. Label the front of every figure with the figure number. Lettering on figures should be large enough to be legible after reduction to single-column width of 21 picas (about 3 inches or 9 cm). Type sizes after reduction should be 6-8 points. Do not use varying letter type sizes within a single figure; use the same size or similar sizes throughout the drawing. Figures should be ready, in all respects, for direct reproduction. All panels of a multipart figure should be provided in the same file. If symbols are not explained on the face of the figure, only standard print characters may be used. Include figure titles in the legend and not on the figure itself. Photomicrographs and electron micrographs must be labeled with a magnification calibration in micrometers or Angstrom units. A statement concerning the magnification must appear in the figure legend.
The cost of publishing color figures will be billed to authors at a rate of $400 per figure. If the corresponding author is an ASPET member in good standing when the paper is published and the referees and editor agree that color is necessary to convey the desired information, then the rate is $200 per figure. Multiple-part figures submitted as separate illustrations are charged as separate figures. A color authorization form will be provided and must be completed prior to publication.
Schemes should be placed after tables, but before figures. Appendices should be placed after tables and figures.
14. Supplemental data. Materials that cannot be presented in print may be published online as supplemental data. These materials are subject to the same review process as the rest of the manuscript. Supplemental data must be cited in the text.
The acceptable formats for supplemental data are Adobe PDF, .gif, .html, .jpg, Microsoft AVI video, MPEG movie, and QuickTime video. Files may be compressed using the ZIP® compression utility.
Except for videos, supplemental data must be labeled with the article's authors and title and the journal title. This is to identify the source article of the supplemental data should a reader print the file. The label should be placed at the top of the page. Data supplement pages will be neither edited nor formatted by ASPET. They should be prepared with the reader in mind. For example, legends should appear below figures instead of on separate pages. Text may be single spaced and put in columns for easier reading.
Videos should be submitted in QuickTime 3.0 or higher format and may be prepared on either a PC or Mac computer. All videos should be submitted at the desired reproduction size and length. To avoid excessive delays in downloading the files, videos must be no more than 5 MB in size and 30 to 60 seconds in length. Authors are encouraged to use QuickTime's "compress" option when preparing files to help control file size. Additionally, cropping frames and image sizes can significantly reduce file sizes. Files submitted can be looped to play more than once, provided file size does not become excessive. Authors will be notified if problems exist with videos as submitted and will be asked to modify them. No editing will be done to the videos at the editorial office. All changes are the responsibility of the author. IMPORTANT: One traditional still image of the author's choosing must be submitted per video. This image will be published to act as a link from the text to the full video file. It will also appear in the text of the printed journal in place of the video. Please indicate clearly in your text whether a figure has a video associated with it and be sure to indicate the name of the corresponding video file. A brief figure legend should also be provided. The figures should be prepared using the guidelines for figures indicated earlier in these instructions.
Accelerated Communications
To provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts may be submitted as Accelerated Communications. Accelerated Communications should present novel results that are clearly documented and make a conceptual advance in their field. They are not intended for publication of preliminary results. Manuscripts submitted under this category should be accompanied by a cover letter that highlights the significance of the work and includes a list of at least three scientists who would be appropriate reviewers. Accelerated Communications will receive expedited reviews, using the same criteria applied to regular papers, with the objective of reaching a decision within four weeks after receipt. It is anticipated that Accelerated Communications will be published essentially as submitted. Manuscripts requiring minor (but significant) revisions will be returned for appropriate changes. Manuscripts requiring major revisions or that fail to meet the criteria for Accelerated Communications will be returned to the authors for revision and considered as regular submissions.
Accelerated Communications should be submitted in the same format as regular manuscripts, but the Results and Discussion sections may be combined at the discretion of the authors. Manuscripts must not exceed five printed pages in the journal. This corresponds approximately to 25 double-spaced typewritten pages, including all components of the manuscript and counting each figure as a page of typewritten text. Manuscripts exceeding these limitations will be considered as regular papers.
Minireviews
From time to time Molecular Pharmacology publishes short, focused reviews or commentary on important or emerging topics related to any aspect of modern molecular pharmacology. Inquiries or suggestions for topics or authors should be directed to our Minireview Editor, Dr. David Sibley, Molecular Neuropharmacology Section, NINDS/NIH, Room 4S-04, 5625 Fishers Ln, MSC 9405, Bethesda, MD 20892-9405; fax: 301-496-9316; sibley@helix.nih.gov.
Reagents
As a condition of publication the authors agree, whenever available quantities allow, to distribute freely to academic researchers for their own use any reagents (e.g., novel chemicals, DNA, antibodies) developed for the published study that are not available from commercial suppliers. Nucleic acid and protein sequences, as well as X-ray crystallographic coordinates, must be deposited in the appropriate databases with a release date no later than the publication date. Sequence accession numbers must be provided in the text.
Drugs
Generic drug names are used in text, tables, and figures. Trade names may be given in parentheses following the first text reference, but should not appear in titles, figures, or tables. Whereas trade names are capitalized, generic or chemical names are not. The chemical structure of new compounds (or a citation to the published structure) must be given. The form used in calculating concentrations (e.g., base or salt) must be indicated.
Receptor Nomenclature
The nomenclature used to identify receptors and ion channels should conform to guidelines of the Committee on Receptor Nomenclature and Drug Classification of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR). These are published periodically in Pharmacological Reviews and are accessible at www.iuphar-db.org/nomenclature.html.
Page and Illustration Charges
Authors are assessed $80 per printed page ($40 for ASPET members) for an accepted manuscript. Authors will receive with their page proof a request for information concerning such charges. The cost of color illustrations will be assigned to the authors (see Figures). Questions on business matters should be directed to the Journals Director, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995; telephone: (301) 634-7060; fax: (301) 634-7158; e-mail: info@aspet.org.
Revised Manuscripts
Revised manuscripts must be submitted within the designated time and must contain an itemized list of all changes made, or a rebuttal, in response to each of the reviewers' suggestions. Do not neglect to retrieve the Revision Checklist to correct any publishing format deficiencies pertaining to your manuscript. Make sure source files are included, figures conform to specifications (see Figures) and the Abstract metadata box is updated, with special characters coded. Publication of accepted papers will be delayed pending correction of any outstanding deficiencies.
After Acceptance
Authors will receive an e-mail message with a user name and password to access their page proofs online. Proofs should be printed out, corrected, and mailed to the compositor. Complete instructions will be included with the page proofs. Authors will be billed for substantial changes to page proofs, which must be returned within 48 hours after receipt. In exceptional cases, a "Note added in proof"; may be published with the Editor's approval. An order form for reprints will be included with the page proofs.
Submission Checklist
____ Letter of submission
____ Authorship Responsibility, Financial Disclosure and Copyright Transfer form signed by all authors
____ Manuscript handling fee of $50.00
____ Running title page includes the number of text pages, tables, figures and references, and the number of words in the Abstract, Introduction and Discussion
____ Manuscript double spaced throughout including references, tables, and figure legends
____ References checked for accuracy (number not to exceed 40)
Editorial Board
Editorial Board
EDITOR: P. JEFFREY CONN, Vanderbilt University
ASSOCIATE EDITORS: PAUL DENT, Virginia Commonwealth University
ALFRED L. GEORGE, Vanderbilt University
STEVEN GRANT, Medical College of Virginia
LEE M. GRAVES, University of North Carolina
RICHARD B. KIM, University of Western Ontario
DIANNE M. PEREZ, Cleveland Clinic Foundation, Ohio
HUGH ROSEN, The Scripps Research Institute
STEPHEN F. TRAYNELIS, Emory University
MINIREVIEW EDITOR: DAVID R. SIBLEY, National Institutes of Health
EDITORIAL AND ADVISORY BOARD
Myles Akabas, Albert Einstein College of Medicine
Jacques Barhanin, Inst de Pharmacologie Molculaire
Giuseppe Battaglia,I.N.M. Neuromed, Italy
Jeffrey L. Benovic, Thomas Jefferson University
Nigel J.M. Birdsall, National Institute for Medical Research, Mill Hill, United Kingdom
Randy Blakely, Vanderbilt University
Julie A. Blendy, University of Pennsylvania School of Medicine
Kendall J. Blumer, Washington University School of Medicine
Michel Bouvier, University of Montreal, Canada
Thomas P. Burris, The Scripps Research Institute
William A. Catterall, University of Washington School of Medicine
Srikumar P. Chellappan, University of Southern Florida
Arthur Christopoulos, Monash University
Richard B. Clark, University of Texas, Houston
Phillip A. Dennis, National Institutes of Health
David L. DeWitt, Michigan State University
George Dubyak, Case Western Reserve University School of Medicine
Ronald S. Duman, Yale University School of Medicine
Frederick J. Ehlert, University of California, Irvine
Michael Freissmuth, Inst of Pharmacology, University of Vienna
Yoshiaki Fujii-Kuriyama, Tohoku University
Ulrik Gether, University of Copenhagen
Robert I. Glazer, Georgetown University Medical Center
Catherine Godson, University College of Dublin
Frank J. Gonzalez, National Cancer Institute
Michael M. Gottesman, National Institutes of Health
Robert M. Graham, Victor Chang Cardiac Research Institute
Jennifer R. Grandis, University of Pittsburgh
Randy A. Hall, Emory University
R. Adron Harris, University of Texas at Austin
John R. Hepler, Emory University School of Medicine
Peter J. Houghton, St. Jude Children's Research Hospital
Kenneth A. Jacobson, National Institutes of Health
Andrew Jenkins,Emory University Medical School
Eric F. Johnson, The Scripps Research Institute
Peter Kalivas, Medical Institute of South Carolina
Marcelo Kazanietz, University of Pennsylvania School of Medicine
Brian K. Kobilka, Stanford University
Herman Koepsell, University of Wurzburg Medical School
Rakesh Kukreja, Virginia Commonwealth University
Ping-Yee Law, University of Minnesota
L.M. Fredrik Leeb-Lundberg, University of Texas Health Science Center
Henry Lester, California Institute of Technology
Lian Li, Emory University School of Medicine Stephen B. Liggett, University of Cincinnati Medical Center
Thomas M. Lincoln, University of Alabama at Birmingham
Richard B. Lock, Children's Cancer Institute Australia for Medical Research
Sophie Lotersztajn, INSERM U581, Creteil, France
Peter Mackenzie, Flinders Medical Center, Australia
Sridhar Mani, Albert Einstein College of Medicine, New York
David Manning, University of Pennsylvania School of Medicine
Donald H. Maurice, Queen's University at Kingston
Andrew McCammon, University of California, San Diego
James A. McCubrey, East Carolina University
James O. McNamara, Duke University Medical Center
Kathryn E. Meier, Medical University of South Carolina
Martin Michel, Academisch Medisch Centrum, The Netherlands
Laurence Miller, Mayo Clinic Medical School and Foundation
Graeme Milligan, University of Glasgow, Scotland
Neil M. Nathanson, University of Washington School of Medicine
Richard R. Neubig, University of Michigan
Kim A. Neve, Veterans Affairs Medical Center, Portland
Robert A. Nicholas, University of North Carolina at Chapel Hill
Sanjay K. Nigam, University of California, San Diego
R. Alan North, University of Manchester, United Kingdom
Robert E. Oswald, Cornell University
Krzysztof Palczewski, Case Western Reserve University
Gavril W. Pasternak, Memorial Sloan-Kettering Cancer Center
Tarun Patel, University of Tennessee, Memphis
Jean-Philippe Pin, Ctr Nat de la Recherche Scientifique
Alvaro Puga, University of Cincinnati Medical Center
Roland Reinehr, University of Duesseldorf
John J. Reiners, Jr., Wayne State University
Des R. Richardson,University of Sydney, Australia
Michael B. Robinson, Children's Hospital of Philadelphia
Michael A. Rogawski, University of California-Davis
Elliott M. Ross, University of Texas Southwestern Medical Center
Bryan L. Roth, Case Western Reserve University School of Medicine
Carol A. Rouzer, Vanderbilt University School of Medicine
Arnold E. Ruoho, University of Wisconsin Medical School
Jill Siegfried, University of Pittsburgh
Shinvendra V. Singh, University of Pittsburgh
Alan Smrcka, University of Rochester
David J. Waxman, Boston University
Jurgen Wess, NIDDK, National Institutes of Health
Michael M. White, MCP Hahnemann University
Keith Williams, SUNY Health Science Center at Brooklyn
Richard D. Ye, University of Illinois College of Medicine
BOARD OF PUBLICATIONS TRUSTEES
James E. Barrett, Chair; P. Jeffrey Conn, Randy A. Hall, Michael F. Jarvis, Eric F. Johnson, John S. Lazo,
Edward T. Morgan, Kim A. Neve, David R. Sibley, Mary Vore, and Jeffrey M. Witkin
EXECUTIVE OFFICER OF THE SOCIETY
Christine K. Carrico
JOURNALS DIRECTOR
Richard Dodenhoff
MANAGING EDITOR
Jill Filler
SENIOR EDITORIAL COORDINATOR
Dan Collinge
|
